Page 44 - Yi Chen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

WORLD Channel, which shares the best of public media in news, documentaries and programming, will celebrate Asian American and Pacific Islander Heritage Month with a series of featured documentary films in May sharing the culturally significant stories that represent the more than 20 million Asian or Pacific Islander Americans in the United States, according to the U.S. Census. The films will be broadcast on WORLD Channel and stream on WORLDChannel.org.

in Taiwan May 4, 2021 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that its exclusive global licensee Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., has launched VYZULTA ® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan. Regulatory approval in Taiwan was obtained in March 2020. VYZULTA has also recently received approval in Qatar. In addition to Taiwan, VYZULTA is commercialized in the United States (since 2017), Canada (2019), Arg...

ZYXI earnings call for the period ending March 31, 2021.

Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to Alimera Sciences' First Quarter Fiscal Year 2021 Financial Results and Corporate Update Conference Call. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Participants of this call are advised that the audio of this conference call is being broadcast live over the Internet and is also being recorded by a playback-purposes. A webcast replay of the call will be available approximately one hour after the end of the call through May 13, 202...

and for future value as we continue the development of our clinical assets NCX 470 in glaucoma and NCX 4251 in blepharitis.” Latanoprostene bunod, the pharmaceutical active ingredient in VYZULTA, was invented and patented by Nicox, and is the first product from the company’s proprietary nitric oxide-donating research platform to be approved for commercialization. Under the patent restoration provisions of the Drug Price Competition and Patent Term Restoration Act of 1984 (also known as the “Hatch-Waxman Act”) certain patents for pharmaceutical products in the U.S. may be extended by...